Phaseline

Companies › Theolytics

Theolytics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
THEO-260
Oncolytic virus
–Phase 1Ovarian CancerSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07211659THEO-260Phase 1Ovarian CancerOncologySep 2027
NCT06618235THEO-260Phase 1Ovarian CancerOncologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.